Renal cell carcinoma: tumor membrane lymphocyte stimulation assay.
A tumor plasma membrane LSA has been developed to measure cell-mediated immunity in patients with renal cell carcinoma. In this assay system, plasma membranes are adjusted to antigenic equivalence with the use of HLA as a plasma membrane marker. Fifteen patients were studied; 6 of 8 had a significant response to autologous tumor (P less than 0.05). Of 7 patients studied with allogeneic tumor, only 1 was responsive. Various parameters of the tumor membrane LSA are discussed, including dose response, kinetics, and method of data presentation.
D000230:Adenocarcinoma / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000008:administration & dosage* / Q000302:isolation & purification; D002462:Cell Membrane / Q000276:immunology; D002478:Cells, Cultured; D006801:Humans; D066298:In Vitro Techniques; D007668:Kidney / Q000276:immunology; D007680:Kidney Neoplasms / Q000276:immunology*; D008213:Lymphocyte Activation; D009374:Neoplasms, Experimental / Q000276:immunology; D012015:Reference Standards
D000951:Antigens, Neoplasm